Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 6
2017 19
2018 27
2019 54
2020 78
2021 123
2022 143
2023 125
2024 126
2025 188
2026 128

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

929 results

Results by year

Filters applied: . Clear all
Page 1
Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. Heater NK, et al. J Hematol Oncol. 2024 Dec 25;17(1):131. doi: 10.1186/s13045-024-01649-z. J Hematol Oncol. 2024. PMID: 39722028 Free PMC article. Review.
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple …
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pem …
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortés J. Dent RA, et al. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1. Future Oncol. 2023. PMID: 37526149 Free article.
Despite recent treatment advances, the prognosis for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) remains poor. The antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) i …
Despite recent treatment advances, the prognosis for patients with locally recurrent inoperable or metastatic triple-negative …
Triple-negative breast cancer therapy: Current and future perspectives (Review).
Won KA, Spruck C. Won KA, et al. Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16. Int J Oncol. 2020. PMID: 33174058 Free PMC article. Review.
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases. TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and therefore do not respond to hormonal or anti-HER2 therapies. ...Recent advanc …
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases. TNBCs lack estrogen …
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.
Yang Z, Liu X, Zhu J, Chai Y, Cong B, Li B, Gao W, Hu Y, Wen M, Liu Y, Fu L, Cao X. Yang Z, et al. Cancer Cell. 2025 Jan 13;43(1):86-102.e10. doi: 10.1016/j.ccell.2024.11.008. Epub 2024 Dec 12. Cancer Cell. 2025. PMID: 39672166 Free article.
Deciphering mechanisms for cancer immune escape may provide targets for improving immunotherapy efficacy. By in vivo genome-wide CRISPR loss-of-function screening in a mouse model of triple negative breast cancer (TNBC), we uncovered a no …
Deciphering mechanisms for cancer immune escape may provide targets for improving immunotherapy efficacy. By in vivo genome-wide CRIS …
Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D. Kwapisz D. Cancer Immunol Immunother. 2021 Mar;70(3):607-617. doi: 10.1007/s00262-020-02736-z. Epub 2020 Oct 5. Cancer Immunol Immunother. 2021. PMID: 33015734 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone (PgR) receptors as well as human epidermal growth factor receptor 2 (HER2) and is associated with poor prognosis. ...Moreover, it seem …
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progest …
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Dent R, Shao Z, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Ramírez EM, Basaran G, Stradella A, Mathiba R, Chen SC, Shen K, Wéber Á, Battelli N, Niikura N, Luo T, Chae YS, Fischbach N, Garbaos G, Patera A, Zhao K, Vuković P, Maxwell MJ, Traina T; TROPION-Breast02 investigators. Dent R, et al. Ann Oncol. 2026 Apr 3:S0923-7534(26)00130-4. doi: 10.1016/j.annonc.2026.03.008. Online ahead of print. Ann Oncol. 2026. PMID: 41937088 Free article.
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. ...CONCLUSIONS: Dato-DX …
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative …
Immunotherapy in Triple-Negative Breast Cancer.
Tiberi E, Parisi A, Pistelli M, Savini A, Galassi F, Reschini C, Quintavalle D, Napoleoni R, Ferrari C, Berardi R. Tiberi E, et al. Oncol Ther. 2025 Sep;13(3):547-575. doi: 10.1007/s40487-025-00346-2. Epub 2025 May 26. Oncol Ther. 2025. PMID: 40418298 Free PMC article. Review.
The PD-1 inhibitor, pembrolizumab, combined with neoadjuvant chemotherapy, improved event-free survival and is a new standard of care for patients with high-risk, early stage triple-negative breast cancer (TNBC), regardless of tumor PD- …
The PD-1 inhibitor, pembrolizumab, combined with neoadjuvant chemotherapy, improved event-free survival and is a new standard of care for pa …
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review.
Jie H, Ma W, Huang C. Jie H, et al. Breast Cancer (Dove Med Press). 2025 Mar 17;17:265-274. doi: 10.2147/BCTT.S516542. eCollection 2025. Breast Cancer (Dove Med Press). 2025. PMID: 40124876 Free PMC article. Review.
Triple-negative breast cancer (TNBC) has become the most aggressive and worst prognostic subtype of breast cancer due to the lack of estrogen receptor, progesterone receptor and HER2 expression. ...In terms of targeted therapy, PARP inhibitors a …
Triple-negative breast cancer (TNBC) has become the most aggressive and worst prognostic subtype of breas …
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E, Chen N, Nanda R. Michaels E, et al. Clin Breast Cancer. 2024 Jun;24(4):263-270. doi: 10.1016/j.clbc.2024.03.001. Epub 2024 Mar 6. Clin Breast Cancer. 2024. PMID: 38582617 Review.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. ...This finding has led to the investigation of immunotherapy-based approaches for treatm …
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a …
IRE1alpha silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.
Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, He W, Zhang SS, Fu X, Liu J, Mutlu AS, Wang S, Nehring RB, Li X, Tang Q, Li C, Lv X, Dobrolecki LE, Zhang W, Han D, Zhao N, Jaehnig E, Wang J, Wu W, Graham DA, Li Y, Chen R, Peng W, Chen Y, Catic A, Zhang Z, Zhang B, Mustoe AM, Koong AC, Miles G, Lewis MT, Wang MC, Rosenberg SM, O'Malley BW, Westbrook TF, Xu H, Zhang XH, Osborne CK, Li JB, Ellis MJ, Rimawi MF, Rosen JM, Chen X. Xu L, et al. Cell. 2024 Dec 12;187(25):7248-7266.e34. doi: 10.1016/j.cell.2024.09.032. Epub 2024 Oct 16. Cell. 2024. PMID: 39419025 Free PMC article.
Here, we identify the ER stress sensor IRE1alpha as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherapy and prevents the innate immune recognition of immunologically cold triple-negative breast cancer (TNBC) …
Here, we identify the ER stress sensor IRE1alpha as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherap …
929 results